Neovascular Glaucoma from Ocular Ischemic Syndrome Treated with Serial Monthly Intravitreal Bevacizumab and Panretinal Photocoagulation: A Case Report
Table 1
Details of antineovascular and intraocular pressure treatment course of the right eye.
Weeks after presentation
Treatment
IOP (mmHg)
# Meds
Service(s)
First Course
0
IVB #1
42
0
1
None
9
3
G
4
IVB #2
10
2
R
5
None
10
2
G
6
PRP #1 (1118 spots, 225 mW)
19
0
R
8
IVB #3
19
0
R
10
PRP #2 (596 spots, 275 mW)
21
0
R
12
IVB #4
17
0
R
14
PRP #3 (193 spots, 225 mW)
N/A
0
R
16
IVB #5
14
0
R
20
IVB #6
15
0
R
22
PRP #4 (462 spots, 200 mW)
N/A
0
R
24
None
19
0
G
Second Course
30
IVB #1
22
0
31
PRP #1 (322 spots, 375 mW)
16
0
R
34
IVB #2
16
0
R
35
PRP #2 (411 spots, 200 mW)
13
0
R
38
IVB #3
10
0
R
40
PRP #3 (560 spots, 200 mW)
N/A
0
R
42
IVB #4
18
0
R
46
PRP #4 (866 spots, 200 mW)
22
0
R
48
None
20
0
G
Third Course
52
IVB #1
27
0
R
54
None
14
1
G
56
IVB #2
13
0
R
Future
Ongoing serial monthly IVB
IVB: intravitreal bevacizumab 1.25 mg in 0.05 ml; PRP: panretinal photocoagulation; O: optometry; G: glaucoma; R: retina spot size for PRP was 400 microns in the first course of treatment and 200 microns in the 2nd course of treatment. Duration was 0.5-0.7 seconds.
